-
公开(公告)号：WO2011008348A2
公开(公告)日：2011-01-20
申请号：PCT/US2010/036247
申请日：2010-05-26
申请人： CALIMMUNE INC. , CHEN, Irvin , AN, Dong Sung , MILLINGTON, Michelle , BOYD, Maureen , SYMONDS, Geoffrey P. , BRETON, Louis Randall
发明人： CHEN, Irvin , AN, Dong Sung , MILLINGTON, Michelle , BOYD, Maureen , SYMONDS, Geoffrey P. , BRETON, Louis Randall
IPC分类号： A01K67/027 , A61K35/28 , A61K48/00 , C07K14/00 , C07K14/16 , C07K14/47 , C12N9/90 , C12N15/85 , C12N15/867 , C12N15/113
CPC分类号： A61K35/28 , A01K67/0271 , A01K2207/12 , A01K2227/105 , A01K2267/0337 , A61K31/713 , A61K38/162 , A61K48/00 , A61K48/0058 , A61K2035/124 , C07K14/00 , C07K14/4702 , C07K2319/03 , C12N5/0647 , C12N7/00 , C12N9/90 , C12N15/1138 , C12N15/86 , C12N2310/14 , C12N2310/531 , C12N2320/30 , C12N2320/31 , C12N2510/00 , C12N2740/16021 , C12N2740/16033 , C12N2740/16043 , C12N2740/16071 , C12N2740/16171 , C12N2740/16222 , C12N2740/16234 , C12N2830/008 , C12N2830/85
摘要： The present invention provides an expression vector for preventing or inhibiting HlV entry, fusion or replication in mammalian cells. In particular, the invention provides a recombinant retroviral vector that encodes an inhibitor of a HlV co-receptor, such as CCR5 or CXCR4, and a protein that inhibits HIV fusion to target cells and/or HIV replication. Pharmaceutical compositions comprising such constructs and methods of use thereof to prevent or treat HIV infection in a patient are also disclosed.
摘要翻译： 本发明提供了用于在哺乳动物细胞中预防或抑制H1V进入，融合或复制的表达载体。 具体而言，本发明提供了编码HIV共受体如CCR5或CXCR4的抑制剂和抑制HIV融合至靶细胞和/或HIV复制的蛋白质的重组逆转录病毒载体。 还公开了包含此类构建体的药物组合物及其用于预防或治疗患者的HIV感染的方法。
-
公开(公告)号：WO2010144773A1
公开(公告)日：2010-12-16
申请号：PCT/US2010/038268
申请日：2010-06-11
申请人： MONELL CHEMICAL SENSES CENTER , BACHMANOV, Alexander, Alexeyevich , BOSAK, Nataliya, Petrovna , ISHIWATARI, Yutaka
CPC分类号： G01N33/5023 , A01K2227/105 , A01K2267/0393 , C12N15/8509 , C12N2830/008 , C12Q1/6897 , G01N33/689 , G01N2500/00
摘要： The present invention relates to a polynucleotide vector comprising the Simian taste-bud specific gene (STG) promoter operatively linked to a reporter gene. In preferred embodiments, the STG promoter is the murine ortholog of the STG promoter. In other preferred embodiments, the STG promoter is the human ortholog of the STG promoter. In some preferred embodiments, the reporter gene is green fluorescent protein (GFP). Additionally provided are vectors comprising the STG promoter operatively linked to a cre-recombinase gene.
摘要翻译： 本发明涉及包含与报告基因有效连接的猿猴味蕾特异性基因（STG）启动子的多核苷酸载体。 在优选的实施方案中，STG启动子是STG启动子的鼠直系同源物。 在其它优选实施方案中，STG启动子是STG启动子的人直向同源物。 在一些优选的实施方案中，报道基因是绿色荧光蛋白（GFP）。 另外提供了包含可操作地连接到重组酶基因的STG启动子的载体。
-
公开(公告)号：WO2010086838A3
公开(公告)日：2010-11-25
申请号：PCT/IB2010050452
申请日：2010-02-02
申请人： ONCOS THERAPEUTICS , HEMMINKI OTTO , BAUERSCHMITZ GERD , CERULLO VINCENZO , PESONEN SARI , HEMMINKI AKSELI
IPC分类号： C12N15/861 , A61K35/76
CPC分类号： A61K38/193 , A61K35/761 , A61K38/177 , A61K48/00 , C12N7/00 , C12N15/86 , C12N2710/10322 , C12N2710/10332 , C12N2710/10343 , C12N2710/10345 , C12N2710/10371 , C12N2830/008 , C12N2830/60 , C12N2830/85 , C12N2840/203
摘要： The present invention relates to the field of medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic human adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to a method of producing an adenoviral vector.
摘要翻译： 本发明涉及医学领域。 具体而言，本发明涉及癌症治疗。 更具体地说，本发明涉及溶瘤的人腺病毒载体和细胞以及包含所述载体的药物组合物。 本发明还涉及所述载体在制备用于治疗受试者的癌症的药物中的用途和治疗受试者中的癌症的方法。 此外，本发明涉及生产腺病毒载体的方法。
-
公开(公告)号：WO2010086838A2
公开(公告)日：2010-08-05
申请号：PCT/IB2010/050452
申请日：2010-02-02
申请人： ONCOS THERAPEUTICS , HEMMINKI, Otto , BAUERSCHMITZ, Gerd , CERULLO, Vincenzo , PESONEN, Sari , HEMMINKI, Akseli
IPC分类号： C12N15/861 , A61K35/76
CPC分类号： A61K38/193 , A61K35/761 , A61K38/177 , A61K48/00 , C12N7/00 , C12N15/86 , C12N2710/10322 , C12N2710/10332 , C12N2710/10343 , C12N2710/10345 , C12N2710/10371 , C12N2830/008 , C12N2830/60 , C12N2830/85 , C12N2840/203
摘要： The present invention relates to the field of medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic human adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to a method of producing an adenoviral vector.
摘要翻译： 本发明涉及药物领域。 具体地，本发明涉及癌症疗法。 更具体地，本发明涉及溶瘤性人腺病毒载体和包含所述载体的细胞和药物组合物。 本发明还涉及所述载体在制备用于治疗受试者中的癌症的药物中的用途以及在受试者中治疗癌症的方法。 此外，本发明涉及一种产生腺病毒载体的方法。
-
公开(公告)号：WO2010084488A1
公开(公告)日：2010-07-29
申请号：PCT/IL2010/000049
申请日：2010-01-19
申请人： RAMOT AT TEL-AVIV UNIVERSITY LTD. , ROSIN-ARBESFELD, Rina , SKLAN, Ella , ZILBERBERG, Alona , DAVID, Naama
CPC分类号： A61K48/0058 , A61K38/164 , C07K14/34 , C07K2319/33 , C07K2319/55 , C12N15/113 , C12N15/85 , C12N2310/141 , C12N2830/008 , C12N2830/85
摘要： The invention provides a nucleic acid construct comprising a promoter sequence derived from microRNA-21 (miR-21) linked to a nucleic acid sequence encoding an anti-cancer agent, an example of which is a toxin. The constructs of the invention are particularly useful for treating tumors expressing miR-21.
摘要翻译： 本发明提供了包含与编码抗癌剂的核酸序列连接的微小RNA-21（miR-21）的启动子序列的核酸构建体，其实例是毒素。 本发明的构建体特别可用于治疗表达miR-21的肿瘤。
-
公开(公告)号：WO2010078198A1
公开(公告)日：2010-07-08
申请号：PCT/US2009/069435
申请日：2009-12-23
发明人： SEKI, Tsugio
CPC分类号： C07K14/71 , C12N15/85 , C12N15/86 , C12N2710/10343 , C12N2830/008
摘要： Regulatory elements for controlling expression of transgenes in angiogenic tissue are provided. One embodiment provides an isolated nucleic acid having at least 80%, 85%, 90%, 95%, 97%, 99% or 100% sequence identity to SEQ ID NO: I, or a fragment thereof that causes expression of a transgene in angiogenic tissue. Vectors containing SEQ ID NO: 1 and one or more transgenes are also provided. A preferred vector is an adenovirus vector. The transgene can encode a cytotoxin, pro-apoptotic polypeptide, or a therapeutic polypeptide. SEQ ID NO:1 regulates the expression of the transgene such that the transgene is only expressed in angiogenic tissue including, but not limited to arteries feeding ischemic tissues. Methods of using vectors containing SEQ ID NO: 1 are also provided.
摘要翻译： 提供了用于控制血管生成组织中转基因表达的调节元件。 一个实施方案提供了与SEQ ID NO：1具有至少80％，85％，90％，95％，97％，99％或100％序列同一性的分离的核酸或其导致转基因表达的片段 血管生成组织。 还提供了含有SEQ ID NO：1的载体和一种或多种转基因。 优选的载体是腺病毒载体。 转基因可编码细胞毒素，促凋亡多肽或治疗性多肽。 SEQ ID NO：1调节转基因的表达，使得转基因仅在血管生成组织中表达，包括但不限于进食缺血组织的动脉。 还提供了使用含有SEQ ID NO：1的载体的方法。
-
公开(公告)号：WO2010075476A2
公开(公告)日：2010-07-01
申请号：PCT/US2009/069343
申请日：2009-12-22
申请人： CALIFORNIA INSTITUTE OF TECHNOLOGY , SAUKA-SPENGLER, Tatjana , MCKEOWN, Sonja, J. , BETACUR, Paola , BRONNER-FRASER, Marianne
IPC分类号： C12N15/113 , C12N15/67 , C12N15/85 , C12N5/0735
CPC分类号： C12Q1/04 , C07K14/4702 , C12N15/111 , C12N15/85 , C12N2330/51 , C12N2830/008 , C12N2830/15 , C12N2830/30 , C12N2830/42 , C12N2830/85 , C12Q1/6881 , C12Q1/6897 , C12Q2600/158
摘要： DNA enhancer sequences are provided for use in constructs to identify early stage embryonic cells. The enhancer sequences can be used in parallel with short-hairpin RNA in a vector construct for endogenously regulated gene knockdowns. The disclosed enhancer sequences can be used to isolate a selected population of early stage embryonic cells.
摘要翻译： 提供DNA增强子序列用于构建体以鉴定早期胚胎细胞。 增强子序列可以与用于内源调节基因敲除的载体构建体中的短发夹RNA平行使用。 所公开的增强子序列可用于分离所选择的早期胚胎细胞群体。
-
58.发明申请DELIVERY OF POLYNUCLEOTIDES ACROSS THE BLOOD BRAIN BARRIER USING RECOMBINANT AAV9 审中-公开使用重组AAV9在血脑屏障上交付多核苷酸
公开(公告)号：WO2010071832A1
公开(公告)日：2010-06-24
申请号：PCT/US2009/068818
申请日：2009-12-18
发明人： KASPAR, Brian, K. , FOUST, Kevin
IPC分类号： A61K48/00
CPC分类号： A61K48/005 , C12N15/86 , C12N2750/14143 , C12N2830/008
摘要： The present invention relates to methods and materials useful for systemically delivering polynucleotides to the spinal cord. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as SMA and ALS as well as Pompe disease and lysosomal storage disorders.
摘要翻译： 本发明涉及用于将多核苷酸系统递送至脊髓的方法和材料。 方法和材料的使用例如用于治疗较低运动神经元疾病如SMA和ALS以及庞培病和溶酶体储存障碍。
-
公开(公告)号：WO2010071454A1
公开(公告)日：2010-06-24
申请号：PCT/NZ2009/000290
申请日：2009-12-17
申请人： AUCKLAND UNISERVICES LIMITED , LAWLOR, Patricia, Alice , YOUNG, Deborah , DURING, Matthew, John
IPC分类号： C12N15/861 , C12N15/63 , A61K48/00 , C12N15/85
CPC分类号： C12N15/86 , A61K48/00 , C12N7/00 , C12N2750/14121 , C12N2750/14143 , C12N2830/008
摘要： The present invention relates to viral vectors and in particular to adeno-associated viral vectors with enhanced gene transfer capabilities into cells of the central nervous system (CNS). The invention has been developed primarily for gene transfer in glial cells and further for the treatment of diseases associated with glial cell pathology.
摘要翻译： 本发明涉及病毒载体，特别涉及具有增强的中枢神经系统细胞（CNS）基因转移能力的腺相关病毒载体。 本发明主要用于胶质细胞中的基因转移，并进一步用于治疗与神经胶质细胞病理学相关的疾病。
-
公开(公告)号：WO2010062975A2
公开(公告)日：2010-06-03
申请号：PCT/US2009/065958
申请日：2009-11-25
申请人： VIRGINIA COMMONWEALTH UNIVERSITY , FISHER, Paul B. , SU, Zao-zhong , LEE, Seok-Geun , SARKAR, Devanand
IPC分类号： A61K48/00
CPC分类号： A61K48/005 , C12N15/113 , C12N2799/022 , C12N2799/06 , C12N2830/008
摘要： Methods, compositions, and therapeutic products for use in the field of oncology and specifically, for the treatment of cancer and other diseases in which SARI is ameliorative or therapeutic and/or small molecule screening for anti-cancer drugs are provided. Cancer specific gene expression using the CCN1 promoter, which is negatively regulated by SARI , for targeting therapeutic molecules in tumors is also provided.
摘要翻译： 用于肿瘤学领域，特别是用于治疗癌症和其他疾病的方法，组合物和治疗产品，其中SARI是改善的或治疗性的和/或用于抗癌的小分子筛选 提供药物。 还提供了使用被SARI负调控的CCN1启动子靶向治疗性分子在肿瘤中的癌症特异性基因表达。
-
-
-
-
-
-
-
-
-
搜索结果
1487 条记录 (耗时 0.026 秒)
